With over 20 years of experience, Cytognos has established itself as a leader in flow cytometry solutions for blood cancer diagnosis, MRD detection, and immune monitoring research. Based in Salamanca, the company's growth strategy revolves around introducing exclusive technologies from research centers and universities. These cutting-edge products have made Cytognos a trusted provider of world-class solutions that address the limitations of current multicolor flow cytometry workflows. In collaboration with the EuroFlow™ consortium, Cytognos implements the Next Generation Flow™ approach, offering highly sensitive flow cytometry tests and standardized protocols for diagnosing, classifying, and monitoring haematological malignancies, MRD, and primary immunodeficiencies.